Scientific Advisory Board Cutaneous T-Cell Lymphoma

Dr. DeSimone is an Associate Professor of Dermatology at the University of Virgina INOVA Fairfax Campus where she serves as the Clerkship Director for cutaneous oncology. She is the Director of Cutaneous Lymphoma at the Inova Schar Cancer Institute, heading a high-volume cutaneous lymphoma subspecialty clinic where she treats over 1,000 lymphoma patients. She is an experienced clinical researcher, serving as principal investigator on numerous Phase 1-3 cutaneous lymphoma trials, and she has authored over 35 peer-reviewed publications. Dr. DeSimone completed a combined Internal Medicine and Dermatology residency at Georgetown University/Medstar and a fellowship in cutaneous oncology at Brigham and Women’s Hospital, focusing on cutaneous lymphoma. She is a member of the International Society for Cutaneous Lymphomas, medical advisor for the Cutaneous Lymphoma Foundation and a member of the U.S. Cutaneous Lymphoma Consortium.  She is an editorial reviewer for the Journal of the American Academy of Dermatology.

Dr. Mangold is a dermatologist with expertise in cutaneous lymphoma and complex medical dermatology, directs the Multi-disciplinary Cutaneous Lymphoma Clinic and is the Chair of Dermatology Research. Dr. Mangold is recognized as an author of over 120 publications. His research focuses on biomarker discovery and targeted therapeutics in rare diseases like CTCL. He is also the Vice Chair of Research Operations Management Team and Medical Director of the Clinical Trial Office at Mayo Clinic Arizona, the Associate Medical Director of Development for Mayo Clinic Enterprise, and a member of the Steering Committee at the Mayo Clinic Center for Clinical and Translational Science. He serves on the board of the U.S. Cutaneous Lymphoma Consortium and was on the board of the Arizona Medical Association and President of the Arizona Dermatology Surgery Society. Dr. Mangold completed his Dermatology Residency at Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine.

Dr. Poligone is the founder and Medical Director of the Rochester Skin Lymphoma Medical Group and the Director of Cancer Biology Research for the Rochester General Hospital Research Institute, where his research focuses on the underlying mechanism of skin cancers.  With over 50 publications in his specialty, Dr. Poligone has been invited to speak at more than 100 meetings on both his scientific studies and clinical knowledge in the field of lymphoma and skin cancer.  He has also served on a number of NIH review committees. Dr. Poligone completed his internship in Internal Medicine at Stanford University, received his MD and PhD at the University of North Carolina at Chapel Hill and trained at Yale University in the field of cutaneous lymphoma.  Dr. Poligone has enrolled over 40 patients while participating in 4 clinical trials evaluating HyBryte™ photodynamic therapy. As such, has treated more patients with HyBryte than any other physician in the world.

Dr. Kim is the Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma at Stanford University. She is an international renowned expert in cutaneous lymphomas and is the Director of the Multi-disciplinary Cutaneous Lymphoma Program and Medical Director of the photopheresis Unit at Stanford Medical Center and is Co-Director of the Lymphoma Research Program at the Stanford Cancer Institute.

Education

She graduated from Stanford University School of Medicine with an MD degree. Dr. Kim is Board Certified in Dermatology.